AU2014328483B2 - Novel immunotherapeutic composition and uses thereof - Google Patents

Novel immunotherapeutic composition and uses thereof Download PDF

Info

Publication number
AU2014328483B2
AU2014328483B2 AU2014328483A AU2014328483A AU2014328483B2 AU 2014328483 B2 AU2014328483 B2 AU 2014328483B2 AU 2014328483 A AU2014328483 A AU 2014328483A AU 2014328483 A AU2014328483 A AU 2014328483A AU 2014328483 B2 AU2014328483 B2 AU 2014328483B2
Authority
AU
Australia
Prior art keywords
seq
ara
peptides
cell
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014328483A
Other languages
English (en)
Other versions
AU2014328483A1 (en
Inventor
Robyn Elizabeth O'hehir
Sara Rachel PRICKETT
Jennifer May ROLLAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aravax Pty Ltd
Original Assignee
Aravax Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903686A external-priority patent/AU2013903686A0/en
Application filed by Aravax Pty Ltd filed Critical Aravax Pty Ltd
Priority to AU2014328483A priority Critical patent/AU2014328483B2/en
Publication of AU2014328483A1 publication Critical patent/AU2014328483A1/en
Application granted granted Critical
Publication of AU2014328483B2 publication Critical patent/AU2014328483B2/en
Priority to AU2020200883A priority patent/AU2020200883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU2014328483A 2013-09-25 2014-09-25 Novel immunotherapeutic composition and uses thereof Active AU2014328483B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2014328483A AU2014328483B2 (en) 2013-09-25 2014-09-25 Novel immunotherapeutic composition and uses thereof
AU2020200883A AU2020200883B2 (en) 2013-09-25 2020-02-07 Novel immunotherapeutic composition and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2013903686 2013-09-25
AU2013903686A AU2013903686A0 (en) 2013-09-25 Novel immunotherapeutic composition and uses thereof
AU2014328483A AU2014328483B2 (en) 2013-09-25 2014-09-25 Novel immunotherapeutic composition and uses thereof
PCT/AU2014/050249 WO2015042664A1 (en) 2013-09-25 2014-09-25 Novel immunotherapeutic composition and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200883A Division AU2020200883B2 (en) 2013-09-25 2020-02-07 Novel immunotherapeutic composition and uses thereof

Publications (2)

Publication Number Publication Date
AU2014328483A1 AU2014328483A1 (en) 2016-04-21
AU2014328483B2 true AU2014328483B2 (en) 2019-11-14

Family

ID=52741648

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014328483A Active AU2014328483B2 (en) 2013-09-25 2014-09-25 Novel immunotherapeutic composition and uses thereof
AU2020200883A Active AU2020200883B2 (en) 2013-09-25 2020-02-07 Novel immunotherapeutic composition and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200883A Active AU2020200883B2 (en) 2013-09-25 2020-02-07 Novel immunotherapeutic composition and uses thereof

Country Status (11)

Country Link
US (3) US11266737B2 (https=)
EP (2) EP3049098A4 (https=)
JP (1) JP7007534B2 (https=)
KR (1) KR20160075532A (https=)
CN (2) CN105992589A (https=)
AU (2) AU2014328483B2 (https=)
BR (1) BR112016006813A2 (https=)
MX (1) MX376449B (https=)
RU (1) RU2689552C2 (https=)
WO (1) WO2015042664A1 (https=)
ZA (1) ZA201602043B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
EP3938053A4 (en) * 2019-03-13 2023-03-22 Psomagen, Inc. EPITOP-BASED APPROACH TO ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE
US20240042016A1 (en) * 2020-12-30 2024-02-08 The Regents Of The University Of Michigan Nanoemulsion vaccine compositions and methods for suppressing reactivity to multiple food allergens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
EP0873135B1 (en) 1995-12-29 2009-07-22 The University of Arkansas Peanut allergens and methods
US6835824B1 (en) * 1995-12-29 2004-12-28 University Of Arkansas Peanut allergens and methods
US20030202980A1 (en) 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
GB2348808B (en) 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
DE69921773D1 (de) 1998-01-16 2004-12-16 Univ Johns Hopkins Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe
AU743647B2 (en) 1998-01-31 2002-01-31 Mt. Sinai School Of Medicine Of New York University Methods and reagents for decreasing allergic reactions
AU3085299A (en) 1998-03-12 1999-09-27 Board Of Trustees Of The University Of Arkansas, The Tertiary structure of peanut allergen ara h 1
AU3717600A (en) 1999-03-02 2000-09-21 Board Of Trustees Of The University Of Arkansas, The Methods and reagents for decreasing clinical reaction to allergy
WO2000051647A2 (en) 1999-03-03 2000-09-08 Mount Sinai School Of Medicine Of New York University Animal model of allergies
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
US20020147140A1 (en) 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
RU2285042C2 (ru) 2000-11-16 2006-10-10 Альк-Абелло А/С Новые мутантные аллергены
ATE414773T1 (de) 2000-11-16 2008-12-15 Alk Abello As Mutante allergene
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
MXPA03010037A (es) 2001-05-01 2004-06-30 Univ California Moleculas de fusion y metodos para tratamiento de enfermedades inmunes.
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
CA2499123A1 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US8057800B2 (en) * 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
FI20075063A0 (fi) * 2007-02-01 2007-02-01 Vactech Oy Allergisen herkistymisen estäminen
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
EP2140880B1 (en) 2008-07-04 2012-11-14 HAL Allergy Holding B.V. Modification of allergens
EP2331124A1 (en) 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2478373B1 (en) 2009-09-14 2019-01-09 Icahn School of Medicine at Mount Sinai Methods for characterizing antibody binding affinity and epitope diversity in food allergy
WO2011106645A1 (en) 2010-02-26 2011-09-01 Benaroya Research Institute Direct analysis of antigen-specific immune response
US8835361B2 (en) 2010-06-01 2014-09-16 The Curators Of The University Of Missouri High-throughput quantitation of crop seed proteins
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20140080730A1 (en) 2011-03-20 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Method for predicting severity of allergic reaction
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
JP2013040138A (ja) 2011-08-17 2013-02-28 Univ Of Tsukuba 活性化型リコンビナント花粉アレルゲンの作製方法
WO2013036301A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for inducing regulatory b cells
CN102533781B (zh) 2011-12-30 2013-09-11 华南师范大学 花生2s-4b蛋白在诱导细胞凋亡中的应用
CN102816232B (zh) 2011-12-30 2014-07-16 华南师范大学 花生2s-4b蛋白及其生产方法
CA2861003C (en) 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
AU2012382406B2 (en) 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
DK2914285T3 (en) 2012-11-01 2017-02-27 Veterinærinstituttet New fusion proteins for the treatment of allergic diseases
MY193724A (en) 2013-03-15 2022-10-27 Sementis Ltd Immune modulation
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PRICKETT, S.R. ET AL., "Ara h 1 CD 4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic", CLINICAL & EXPERIMENTAL ALLERGY, (2013-06), vol. 43, no. ISSUE, pages 684 - 697 *
PRICKETT, S.R. ET AL., "Ara h 2 peptides containing dominant CD 4+ T- cell epitopes: Candidates for a peanut allergy therapeutic", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (2011-03), vol. 127, no. 3, pages 608 - 615 .E5 *

Also Published As

Publication number Publication date
US11266737B2 (en) 2022-03-08
AU2020200883B2 (en) 2022-05-12
AU2020200883A1 (en) 2020-02-27
RU2016115732A (ru) 2017-10-30
US20220280637A1 (en) 2022-09-08
ZA201602043B (en) 2022-08-31
JP7007534B2 (ja) 2022-01-24
WO2015042664A1 (en) 2015-04-02
RU2016115732A3 (https=) 2018-06-19
EP4710935A3 (en) 2026-05-06
US20160375130A1 (en) 2016-12-29
CN105992589A (zh) 2016-10-05
EP3049098A1 (en) 2016-08-03
US11986522B2 (en) 2024-05-21
CN121714673A (zh) 2026-03-24
AU2014328483A1 (en) 2016-04-21
CA2925480A1 (en) 2015-04-02
RU2689552C2 (ru) 2019-05-28
EP4710935A2 (en) 2026-03-18
JP2016533341A (ja) 2016-10-27
BR112016006813A2 (pt) 2017-09-19
US20240415955A1 (en) 2024-12-19
EP3049098A4 (en) 2017-08-16
MX376449B (es) 2025-03-07
MX2016003363A (es) 2016-09-23
KR20160075532A (ko) 2016-06-29

Similar Documents

Publication Publication Date Title
US11986522B2 (en) Immunotherapeutic composition and uses thereof
AU2019240574B2 (en) Novel immunotherapeutic molecules and uses thereof
HUE027237T2 (en) Compositions and methods for treatment of celiac disease
CA2925480C (en) Novel immunotherapeutic composition and uses thereof
AU2005252268B2 (en) Novel immunointeractive molecules and uses thereof
AU780049B2 (en) Immunointeractive molecules and their uses in treating subjects suffering from HEV B 5 allergies
AU2003213861A1 (en) Immunotherapeutic and immunoprophylactic reagents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)